How A Leading Global Pharmaceutical Company Accelerated Enrollment In MDD And PTSD Study

Challenge:

A large, global pharmaceutical sponsor launched a study to increase their knowledge around potential biomarkers for major depressive disorder (MDD) and post-traumatic stress disorder (PTSD). Recruitment for the study proved challenging for a variety of reasons. The study itself required participants to stay in the clinic for 24-hour periods. During these 24-hour periods, male and female patients were both present, a situation that made participation more difficult for female patients suffering from PTSD stemming from trauma that involved a male. Unlike other studies, this program was not researching a new therapy, nor was the sponsor able to offer financial compensation to participants. Finally, the potential study participant population was already limited to patients living within the geographic areas connected with only four clinical trial sites.

Find out more in the available case study.